Kruyt FAE - Search Results

1

Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor.

Hiltermann TJN, Pore MM, van den Berg A, Timens W, Boezen HM, Liesker JJW, Schouwink JH, Wijnands WJA, Kerner GSMA, Kruyt FAE, Tissing H, Tibbe AGJ, Terstappen LWMM, Groen HJM. Hiltermann TJN, et al. Among authors: kruyt fae. Ann Oncol. 2012 Nov;23(11):2937-2942. doi: 10.1093/annonc/mds138. Epub 2012 Jun 11. Ann Oncol. 2012. PMID: 22689177 Free article.

2

Targeting apoptosis pathways in lung cancer.

Pore MM, Hiltermann TJ, Kruyt FA. Pore MM, et al. Cancer Lett. 2013 May 28;332(2):359-68. doi: 10.1016/j.canlet.2010.09.012. Epub 2010 Oct 25. Cancer Lett. 2013. PMID: 20974517 Review.

3

Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung Cancer.

Pore M, Meijer C, de Bock GH, Boersma-van Ek W, Terstappen LW, Groen HJ, Timens W, Kruyt FA, Hiltermann TJ. Pore M, et al. Clin Lung Cancer. 2016 Nov;17(6):535-542. doi: 10.1016/j.cllc.2016.05.015. Epub 2016 Jun 8. Clin Lung Cancer. 2016. PMID: 27363902

4

Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer.

Vischioni B, van der Valk P, Span SW, Kruyt FA, Rodriguez JA, Giaccone G. Vischioni B, et al. Ann Oncol. 2004 Nov;15(11):1654-60. doi: 10.1093/annonc/mdh436. Ann Oncol. 2004. PMID: 15520067 Free article.

5

TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives.

Stegehuis JH, de Wilt LH, de Vries EG, Groen HJ, de Jong S, Kruyt FA. Stegehuis JH, et al. Drug Resist Updat. 2010 Feb-Apr;13(1-2):2-15. doi: 10.1016/j.drup.2009.11.001. Epub 2009 Dec 29. Drug Resist Updat. 2010. PMID: 20036602 Review.

6

A unique small cell lung carcinoma disease progression model shows progressive accumulation of cancer stem cell properties and CD44 as a potential diagnostic marker.

Heng WS, Pore M, Meijer C, Hiltermann TJN, Cheah SC, Gosens R, Kruyt FAE. Heng WS, et al. Among authors: kruyt fae. Lung Cancer. 2021 Apr;154:13-22. doi: 10.1016/j.lungcan.2021.02.002. Epub 2021 Feb 12. Lung Cancer. 2021. PMID: 33607458 Free article.

7

Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients.

Ferreira CG, van der Valk P, Span SW, Jonker JM, Postmus PE, Kruyt FA, Giaccone G. Ferreira CG, et al. Ann Oncol. 2001 Jun;12(6):799-805. doi: 10.1023/a:1011167113067. Ann Oncol. 2001. PMID: 11484955 Free article. Clinical Trial.

8

Embryological signaling pathways in Barrett's metaplasia development and malignant transformation; mechanisms and therapeutic opportunities.

Pavlov K, Meijer C, van den Berg A, Peters FT, Kruyt FA, Kleibeuker JH. Pavlov K, et al. Crit Rev Oncol Hematol. 2014 Oct;92(1):25-37. doi: 10.1016/j.critrevonc.2014.05.002. Epub 2014 May 12. Crit Rev Oncol Hematol. 2014. PMID: 24935219 Review.

9

GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma.

Pavlov K, Honing J, Meijer C, Boersma-van Ek W, Peters FT, van den Berg A, Karrenbeld A, Plukker JT, Kruyt FA, Kleibeuker JH. Pavlov K, et al. Dig Liver Dis. 2015 Jan;47(1):73-80. doi: 10.1016/j.dld.2014.09.014. Epub 2014 Oct 16. Dig Liver Dis. 2015. PMID: 25445407

10

Global histone modifications predict prognosis of resected non small-cell lung cancer.

Barlési F, Giaccone G, Gallegos-Ruiz MI, Loundou A, Span SW, Lefesvre P, Kruyt FA, Rodriguez JA. Barlési F, et al. J Clin Oncol. 2007 Oct 1;25(28):4358-64. doi: 10.1200/JCO.2007.11.2599. J Clin Oncol. 2007. PMID: 17906200

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

133 results

Search Page